

## DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference

CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm Eastern Time. The conference is being held at the New York Palace Hotel in New York City.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

To access the live presentation via the internet, please go to the direct conference link at:

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=DRRX&item\_id=2539284 or to the DURECT Investor Relations tab at www.www.durect.com.

## About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(TM), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

## **SOURCE DURECT Corporation**

Matthew J. Hogan, Chief Financial Officer of DURECT Corporation, +1-408-777-4936